CVS Health (CVS) Tops Q4 EPS by 6c, Offers FY Guidance

CVS Health (NYSE: CVS) reported Q4 EPS of $1.30, $0.06 better than the analyst estimate of $1.24. Revenue for the quarter came in at $69.55 billion versus the consensus estimate of $68.73 billion.

GUIDANCE:

CVS Health sees FY2021 EPS of $7.39-$7.55, versus the consensus of $7.54.

• The Company's full year 2021 GAAP diluted EPS from continuing operations is projected to be in the range of $6.06 to $6.22, and full year 2021 Adjusted EPS is projected to be in the range of $7.39 to $7.55. The Company's full year 2021 cash flow from operations is projected to be in the range of $12.0 billion to $12.5 billion.
• The adjustments between GAAP diluted EPS from continuing operations and Adjusted EPS include, as applicable, adding back amortization of intangible assets, as well as integration costs related to the Company's acquisition (the "Aetna Acquisition") of Aetna Inc. ("Aetna").

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• RH (RH) Tops Q1 EPS by 12c
• Limoneira (LMNR) Misses Q2 EPS by 8c, Beats on Revenue
• CVS adds Zepbound back to formulary, expands GLP-1 coverage